
    CELLCO PARTNERSHIP (doing business as Verizon Wireless), Plaintiff-Appellant, v. BROADCOM CORPORATION, Defendant-Appellee.
    No. 2006-1514.
    United States Court of Appeals, Federal Circuit.
    March 19, 2007.
    Aaron M. Panner, Kellogg, Huber, Hansen, Todd, Evans & Figel, P.L.L.C., of Washington, DC, argued for plaintiff-appellant. With him on the brief were Mark C. Hansen, Richard H. Stern, and Michael E. Joffre. Of counsel on the brief were John Thorne and Robert H. Griffen, Verizon, of Arlington, Virginia; Richard Cullen, Brian C. Riopelle, and Robert M. Tyler, McGuireWoods LLP, of Richmond, Virginia; David L. Shapiro, of Cambridge, Massachusetts; and James H. Wallace, Jr., John B. Wyss, and Kevin P. Anderson, Wiley Rein LLP, of Washington, DC.
    Michael H. Page, Keker & Van Nest, LLP, of San Francisco, California, argued for defendant-appellee. With him on the brief were Robert A. Van Nest and Steven A. Hirsch.
    Before MAYER, Circuit Judge, PLAGER, Senior Circuit Judge, and PROST, Circuit Judge.
   PER CURIAM.

In light of MedImmune, Inc. v. Genentech, Inc., 549 U.S.-, 127 S.Ct. 764, 166 L.Ed.2d 604 (2007), we conclude that the district court erred as a matter of law in holding that no actual controversy existed between the parties, as required by the Declaratory Judgment Act, 28 U.S.C. § 2201(a) and Article III of the Constitution. See id. at-n. 11, 127 S.Ct. at 774 n. 11. However, MedImmune also reaffirmed that trial courts have “unique and substantial discretion” in determining whether to decide cases over which they have declaratory judgment jurisdiction. Id. at-, 127 S.Ct. at 776 (quoting Wilton v. Seven Falls Co., 515 U.S. 277, 286, 115 S.Ct. 2137, 132 L.Ed.2d 214 (1995)).

The same patents at issue here are also the subject of a pending International Trade Commission (“ITC”) proceeding, which was instituted by Broadcom Corporation (“Broadcom”) against Qualcomm Corporation (“Qualcomm”). Qualcomm manufactures the chips used by Célico Partnership (“Célico”). That proceeding raised many of the same issues as Cellco’s declaratory judgment action, including the validity of the patents. Although the ITC’s findings lack preclusive effect and cannot conclusively resolve the controversy between Célico and Broadcom, they can be considered by federal courts for their persuasive value. Texas Instruments v. Cypress Semiconductor Corp., 90 F.3d 1558, 1568-69 (Fed.Cir.1996).

In addition, a separate district court proceeding raising similar issues was pending between Qualcomm and Broadcom in the Central District of California. As required by statute, that case was stayed at Qualcomm’s request until the ITC’s determination becomes final. 28 U.S.C. § 1659(a); see In re Princo Corp., 478 F.3d 1345 (Fed.Cir.2007) (order). When that suit resumes, it will have the benefit of the ITC’s determinations, and Célico can seek to intervene.

In light of these other proceedings involving the chip manufacturer, the trial court determined that entertaining Cellco’s declaratory judgment action would be “an inappropriate use of multiple judicial districts.” Because of potential judicial efficiency, and because Célico has not shown sufficient harm to require immediate resolution of its case prior to the conclusion of these other proceedings, we find no abuse of discretion in dismissing the case. Accordingly, we affirm.  